Seagen Overview

  • Founded
  • 1998

Founded
  • Status
  • Public

  • Employees
  • 2,675

Employees
  • Stock Symbol
  • SGEN

Stock Symbol
  • Investments
  • 5

  • Share Price
  • $178.33

  • (As of Monday Closing)

Seagen General Information

Description

Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

Contact Information

Website
www.seagen.com
Formerly Known As
Seattle Genetics, Inc., Seattle Genetics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Primary Office
  • 21717 30th Drive Southeast, Building 3
  • Suite 21823
  • Bothell, WA 98021
  • United States
+1 (425) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Seagen Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$178.33 $175.81 $105.43 - $192.79 $32.4B 184M 1.41M -$4.04

Seagen Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 30,672,803 25,892,010 29,696,096 18,790,185
Revenue 1,777,873 1,574,371 2,175,536 916,713
EBITDA (658,002) (597,079) 679,085 (125,136)
Net Income (739,796) (674,471) 613,670 (158,650)
Total Assets 3,630,343 3,719,604 4,000,906 2,205,866
Total Debt 50,205 56,665 61,884 77,052
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Seagen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Seagen‘s full profile, request access.

Request a free trial

Seagen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Seagen‘s full profile, request access.

Request a free trial

Seagen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancer
Drug Discovery
Bothell, WA
2,675 As of 2021
00.000
000000&0

000000

boris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate v
0000 000000000
Alameda, CA
000 As of 0000
00000
000000000 00000

00000

voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non p
0000 00000000
South San Francisco, CA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Seagen Competitors (50)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exelixis Formerly VC-backed Alameda, CA 000 00000 000000000 00000
00000 000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
000000 00000000000 Formerly VC-backed San Francisco, CA 000 00.000 000000000 00.000
000000000 Formerly PE-Backed Planegg, Germany 000 00000 000000000 00000
You’re viewing 5 of 50 competitors. Get the full list »

Seagen Patents

Seagen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210221897-A1 Methods of treating cancer with nonfucosylated anti-cd70 antibodies Pending 30-Dec-2019 00000000000
US-20210228676-A1 Combination therapy with liv1-adc and pd-1 antagonist Pending 09-Dec-2019 000000000
US-20210198367-A1 Anti-avb6 antibodies and antibody-drug conjugates Pending 05-Dec-2019 00000000000
AU-2020381495-A1 Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate Pending 15-Nov-2019 0000000000
US-20210101982-A1 Anti-pd-l1 antibodies and antibody-drug conjugates Pending 04-Oct-2019 C07K16/2827
To view Seagen’s complete patent history, request access »

Seagen Executive Team (17)

Name Title Board Seat Contact Info
Clay Siegall Ph.D Co-Founder, President, Chief Executive Officer & Chairman of the Board
Roger Dansey Interim Chief Executive Officer & Chief Medical Officer
Todd Simpson Chief Financial Officer
Vaughn Himes Ph.D Chief Technology Officer, Technology
Jean Liu JD Chief Legal Officer, Legal
You’re viewing 5 of 17 executive team members. Get the full list »

Seagen Board Members (12)

Name Representing Role Since
Alpna Seth Ph.D Self Board Member 000 0000
Clay Siegall Ph.D Seagen Co-Founder, President, Chief Executive Officer & Chairman of the Board 000 0000
Daniel Welch Self Board Member 000 0000
David Gryska Self Board Member 000 0000
Felix Baker Ph.D Self Chairman of the Board 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Seagen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Seagen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Seagen‘s full profile, request access.

Request a free trial

Seagen Investments & Acquisitions (5)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 24-Mar-2021 0000 0000 Drug Discovery 00000000
000000000 000 09-Mar-2018 0000000000 00000 Biotechnology 0000 0000
0000000-00000 01-Oct-2017 000000000 000.00 Buildings and Property 0000 0000
00000 00000 0 01-Aug-2017 0000000000 000.00 Laboratory Services (Healthcare) 000000 00
Cogent Biosciences 11-Jun-2015 Early Stage VC 0000 Biotechnology 0000 0000
To view Seagen’s complete investments and acquisitions history, request access »

Seagen Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 00000000000 24-Mar-2021 0000 0000 Completed
  • 000000
Cogent Biosciences 11-Jun-2015 Early Stage VC 0000 Completed
  • 14 buyers
To view Seagen’s complete exits history, request access »